Mitayani Purwoko, Mochammad Junaidy Heriyanto, Sulistiyani Sulistiyani, Solikah Sriningsih, Chendra Perdana Putra, Rima January Putri Ridwan Gani, Denny Anggoro Prakoso, Erlina Krisdianita Novitasari, Gladys Dwiani Tinovella Tubarad, Rizky Triutami Sukarno, Waluyo Rudiyanto, Gea Pandhita, Nurita Aziza, Yanuarita Tursinawati, Muhammad Perdana Airlangga, Meddy Setiawan, M. Mansyur Romi

SKRINING FUNGSI KOGNITIF DAN KADAR ASAM URAT PADA PESERTA PROLANIS KLINIK DOKTER KELUARGA

Introduction

Skrining fungsi kognitif dan kadar asam urat pada peserta prolanis klinik dokter keluarga. Skrining fungsi kognitif dan kadar asam urat pada peserta Prolanis lansia di Klinik Dokter Keluarga. Hasil menunjukkan mayoritas memiliki fungsi kognitif dan kadar asam urat normal.

Abstract

ABSTRAK Fungsi kognitif dan kadar asam urat darah lansia tidak termasuk dalam pemeriksaan wajib dalam program Prolanis. Fungsi kognitif perlu dinilai untuk memastikan bahwa peserta Prolanis tidak mengalami kemunduran fungsi kognitif. Tujuan kegiatan ini adalah untuk melakukan skrining tingkat fungsi kognitif dan kadar asam urat darah peserta Prolanis di Klinik Dokter Keluarga Fakultas Kedokteran Universitas Muhammadiyah Palembang. Kegiatan dilaksanakan dalam satu hari selama 2 jam 30 menit. Pemeriksaan fungsi kognitif dilakukan menggunakan kuesioner Mini Mental State Examination (MMSE) berbahasa Indonesia. Pemeriksaan kadar asam urat darah dilakukan menggunakan darah dari ujung jari dengan alat pemeriksa asam urat dan strip khusus. Hasil skrining menunjukkan bahwa 80,4% peserta Prolanis memiliki fungsi kognitif yang normal dan 66,7% memiliki kadar asam urat darah yang normal. ABSTRACT Cognitive function and blood uric acid levels in the elderly are not included in the mandatory screening in the Prolanis program. Cognitive function needs to be assessed to ensure that Prolanis participants do not experience cognitive decline. The purpose of this activity was to screen the cognitive function and blood uric acid levels of Prolanis participants at the Family Physician Clinic, Faculty of Medicine, Muhammadiyah University of Palembang. The activity was carried out in one day for 2 hours and 30 minutes. Cognitive function testing was conducted using the Indonesian language Mini Mental State Examination (MMSE) questionnaire. Blood uric acid testing was performed using fingertip blood with a uric acid tester and special strips. The screening results showed that 80.4% of Prolanis participants had normal cognitive function and 66.7% had normal blood uric acid levels.

Review

This paper addresses a relevant and important gap in the routine care of elderly participants within the Prolanis program by focusing on cognitive function and uric acid levels, which are currently not mandatory screenings. The title clearly communicates the scope, and the abstract succinctly outlines the rationale: to ensure participants are not experiencing cognitive decline and to assess uric acid levels, given their potential health implications in an aging population with chronic conditions. This initiative serves as a valuable preliminary investigation, highlighting the need for a more holistic assessment approach within existing chronic disease management programs. The methodology employed appears practical and well-suited for a community-based screening activity. The use of the Indonesian Mini Mental State Examination (MMSE) for cognitive assessment is appropriate and an established tool for initial screening. Similarly, the use of fingertip blood for uric acid testing allows for quick, accessible point-of-care measurements, aligning with the "screening" objective. The activity's focused duration (one day, 2.5 hours) suggests an efficient design for initial data collection, although the abstract does not provide details on participant recruitment or sample size, which limits the ability to fully contextualize the findings regarding representativeness and generalizability. The screening results, indicating that 80.4% had normal cognitive function and 66.7% had normal uric acid levels, are significant. Crucially, these figures also reveal that a substantial proportion of participants (19.6% with non-normal cognition and 33.3% with non-normal uric acid) would benefit from further assessment or intervention. This directly supports the authors' premise regarding the utility of these screenings. The findings provide a strong foundation for advocating for the integration of such assessments into the standard Prolanis protocol, thereby enhancing early detection and management strategies for cognitive decline and hyperuricemia in this vulnerable population. Future research could expand on these findings by exploring correlations with specific chronic diseases, conducting longitudinal studies, and assessing the impact of follow-up interventions.

Full Text

Comments

You need to be logged in to post a comment.